Balance Sheet
Accounts PayablesAccumulated ExpensesAssetsCash & Current InvestmentsCash & EquivalentsCommon EquityCurrent AssetsCurrent LeasesGoodwillGoodwill & IntangiblesIntangiblesLiabilities and Shareholders EquityLong-Term InvestmentsNon-Current AssetsNon-Current Deferred Tax LiabilityOperating LeasesOther Non-Current AssetsOther Non-Current LiabilitiesPayablesPrepaid AssetsProperty, Plant & Equipment (Net)ReceivablesReceivables - NetRetained EarningsShareholder's EquityTotal Current LiabilitiesTotal LiabilitiesTotal Non-Current LiabilitiesTreasury Shares
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Cartesian Therapeutics (RNAC) Operating Leases: 2018-2024

Historic Operating Leases for Cartesian Therapeutics (RNAC) over the last 7 years, with Dec 2024 value amounting to $11.1 million.

  • Cartesian Therapeutics' Operating Leases fell 13.98% to $12.6 million in Q3 2025 from the same period last year, while for Sep 2025 it was $12.6 million, marking a year-over-year decrease of 13.98%. This contributed to the annual value of $11.1 million for FY2024, which is 26.67% up from last year.
  • As of FY2024, Cartesian Therapeutics' Operating Leases stood at $11.1 million, which was up 26.67% from $8.8 million recorded in FY2023.
  • Cartesian Therapeutics' Operating Leases' 5-year high stood at $11.1 million during FY2024, with a 5-year trough of $8.6 million in FY2021.
  • Its 3-year average for Operating Leases is $10.0 million, with a median of $10.1 million in 2022.
  • Its Operating Leases has fluctuated over the past 5 years, first surged by 2,493.28% in 2020, then declined by 12.59% in 2023.
  • Yearly analysis of 5 years shows Cartesian Therapeutics' Operating Leases stood at $9.6 million in 2020, then decreased by 10.87% to $8.6 million in 2021, then increased by 16.95% to $10.1 million in 2022, then fell by 12.59% to $8.8 million in 2023, then grew by 26.67% to $11.1 million in 2024.